Medial prefrontal neuroplasticity during extended-release naltrexone treatment of opioid use disorder - a longitudinal structural magnetic resonance imaging study.  Shi Z, Li X, Todaro DR, Cao W, Lynch KG, Detre JA, Loughead J, Langleben DD,...

Loss of Consciousness After Naltrexone Implantation: A Case Report.  Doğan O.  Turk Psikiyatri Derg. 2024 Fall;35(3):245-247. doi: 10.5080/u26711. PMID: 39224997; PMCID: PMC11375739. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1...

Safety of naltrexone in patients with cirrhosis.  Thompson R, Taddei T, Kaplan D, Rabiee A.  JHEP Rep. 2024 Apr 10;6(7):101095. doi: 10.1016/j.jhepr.2024.101095. PMID: 38961852; PMCID: PMC11220533. https://www.jhep-reports.eu/article/...

Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective  NIH-supported clinical trial addresses important barrier to opioid use disorder treatment.  Starting people with opioid use disorder...

Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.  Shulman M, Greiner MG, Tafessu HM, et al.  JAMA Netw Open. 2024;7(5):e249744. doi:10.1001/jamanet...

Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications.  Beauregard ER, Maguire EG.  Ment Health Clin. 2024 Apr 1;14(2):102–6. doi: 10.9740/mhc.2024.04.102. PMCID: PMC11058323. https://ww...